MedTrace Logo

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

NCT02499328 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 340

Last updated 2026-02-11

Study results available
· View outcomes & findings →

Summary

This multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B

Conditions

  • Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

AZD9150

AZD9150

DRUG

MEDI4736

MEDI4736

DRUG

AZD5069

AZD5069

DRUG

tremelimumab (treme)

tremelimumab

Sponsors & Collaborators

  • MedImmune LLC

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Dr David Hong, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-06
Primary Completion
2020-02-28
Completion
2025-10-08
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Germany
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02499328 on ClinicalTrials.gov